JACC:接受短期双重抗血小板治疗的患者氯吡格雷停药后的早期不良事件风险

2017-08-22 xiangting MedSci原创

在植入新一代DES的PCI患者中,3或6个月DAPT后停用氯吡格雷与不良临床事件的早期升高无关。

这项研究旨在评估随机试验中双重抗血小板治疗(DAPT)停药后的临床相关反跳现象。短期DAPT后停用氯吡格雷是否与缺血事件的早期风险相关仍不清楚。研究人员进行了个体参与者数据分析和汇总荟萃分析。主要结局是大的心脏和脑血管不良事件(MACCE),定义为心脏死亡、心肌梗死(MI)或中风的复合。该研究包括11473例PCI患者,来自6项随机试验的个体参与者数据,比较短期DAPT(3或6个月)与长期DAPT(12个月或更长时间)。在氯吡格雷停药后的头90天内,与长期DAPT相比,短期DAPT患者的MACCE风险没有显著增加(风险比[HR]:1.18; 95%置信区间[CI]: 0.71-1.98; p = 0.52;绝对风险差异0.10%; 95%CI:-0.16%-0.36%)。短期DAPT组和长期DAPT组(HR = 0.93; 95%CI:0.46-1.90; p = 0.85)的MI或支架血栓形成风险相近。在11项试验(包括38,919例患者)的综合数据荟萃分析中,长期(≥12个月)DAPT(HR = 2.28; 95%CI:1.69-3.09; p<0.001)的早期MACCE的

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853739, encodeId=b8531853e3912, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 12 00:33:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007389, encodeId=5664200e389e0, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Thu Sep 21 05:33:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325487, encodeId=0421132548e2a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402169, encodeId=6c0414021693c, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460802, encodeId=b57a1460802f8, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235989, encodeId=cebb235989f5, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Aug 22 12:57:51 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-12-12 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853739, encodeId=b8531853e3912, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 12 00:33:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007389, encodeId=5664200e389e0, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Thu Sep 21 05:33:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325487, encodeId=0421132548e2a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402169, encodeId=6c0414021693c, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460802, encodeId=b57a1460802f8, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235989, encodeId=cebb235989f5, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Aug 22 12:57:51 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853739, encodeId=b8531853e3912, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 12 00:33:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007389, encodeId=5664200e389e0, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Thu Sep 21 05:33:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325487, encodeId=0421132548e2a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402169, encodeId=6c0414021693c, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460802, encodeId=b57a1460802f8, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235989, encodeId=cebb235989f5, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Aug 22 12:57:51 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853739, encodeId=b8531853e3912, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 12 00:33:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007389, encodeId=5664200e389e0, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Thu Sep 21 05:33:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325487, encodeId=0421132548e2a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402169, encodeId=6c0414021693c, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460802, encodeId=b57a1460802f8, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235989, encodeId=cebb235989f5, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Aug 22 12:57:51 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853739, encodeId=b8531853e3912, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 12 00:33:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007389, encodeId=5664200e389e0, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Thu Sep 21 05:33:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325487, encodeId=0421132548e2a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402169, encodeId=6c0414021693c, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460802, encodeId=b57a1460802f8, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235989, encodeId=cebb235989f5, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Aug 22 12:57:51 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-08-24 yinhl1980
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853739, encodeId=b8531853e3912, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 12 00:33:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007389, encodeId=5664200e389e0, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Thu Sep 21 05:33:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325487, encodeId=0421132548e2a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402169, encodeId=6c0414021693c, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460802, encodeId=b57a1460802f8, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Aug 24 02:33:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235989, encodeId=cebb235989f5, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Aug 22 12:57:51 CST 2017, time=2017-08-22, status=1, ipAttribution=)]
    2017-08-22 清风拂面

    谢谢分享.学习受益匪浅

    0

相关资讯

做中国研究,集中国证据:研究提示基因型不影响中国ACS患者氯吡格雷治疗结局

近日,国际心脏病学杂志(Int J Cardiol)发表了华中科技大学同济医学院附属同济医院汪道文教授团队的一项研究。与西方相关研究结果不同,此项研究提示,虽然中国患者携带肝细胞色素P450酶(CYP)2C19功能缺失等位基因的频率明显高于欧美人群,但这并不影响接受经皮冠状动脉介入治疗(PCI)的急性冠脉综合征(ACS)患者的临床结局,而且中国患者的心血管不良事件的发生率反而远远低于欧美患者。

Int J Cardiol:普拉格雷可以改善不稳定型心绞痛患者血管内皮NO的生物利用度并减弱血小板白细胞的相互作用!

由此可见,普拉格雷对内皮一氧化氮的生物利用度和炎症标志物具有有益的中期效应。

Am Heart J:糖尿病ACS患者:普拉格雷 vs 氯吡格雷双抗方案

普拉格雷 vs 氯吡格雷双联抗血小板疗法(DAPT)管理糖尿病(DM)合并急性冠脉综合征(ACS)患者的风险特点和治疗反应仍不确定。2017年6月,发表在《Am Heart J》的一项研究显示,阿司匹林+普拉格雷 vs 阿司匹林+氯吡格雷的更强效DAPT方案的治疗作用没有差异。

氯吡格雷抵抗,或与中国人“无关”?

抗血小板治疗是冠心病治疗的重要基石,特别是在支架术后的患者中阿司匹林加氯吡格雷双联抗血小板仍是治疗常规。

JACC:经导管主动脉瓣置换术后阿司匹林与阿司匹林加氯吡格雷抗血栓治疗的比较

这项小型试验显示,SAPT(vs.DAPT)能减少TAVR后主要不良事件的发生。

Am Heart J:行PCI的急性冠脉综合征患者:普拉格雷是否比氯吡格雷更具优势?

普拉格雷曾被誉为有望取代氯吡格雷的药物。但2017年6月,发表在《Am Heart J》的一项研究显示,对于行经皮冠脉介入(PCI)的患者,在当代临床实践中,接受普拉格雷的患者同接受氯吡格雷的患者相比倾向于具有较低的风险。考虑基线差异后,普拉格雷使用相关的较少的缺血和出血事件不再显着。